Protagonist Therapeutics, Inc. (PTGX)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 28.27 |
| Open | 28.57 |
| Bid | 28.17 x 100 |
| Ask | 28.28 x 100 |
| Day's range | 27.94 - 28.76 |
| 52-week range | 13.72 - 33.34 |
| Volume | |
| Avg. volume | 558,577 |
| Market cap | 1.656B |
| Beta (5Y monthly) | 2.08 |
| PE ratio (TTM) | 11.11 |
| EPS (TTM) | 2.54 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.80 |
GuruFocus.comProtagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
Comprehensive Analysis of Q1 2024 Earnings and Strategic Developments
Simply Wall St.We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon
With the business potentially at an important milestone, we thought we'd take a closer look at Protagonist...
GlobeNewswireTurnstone Biologics Appoints William Waddill to its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o
© 2024 Yahoo. All rights reserved.